Imperial College London

ProfessorMarkThursz

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Professor of Hepatology. Head of Department
 
 
 
//

Contact

 

+44 (0)20 3312 1903m.thursz

 
 
//

Assistant

 

Ms Dawn Campbell +44 (0)20 3312 6454

 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Publication Type
Year
to

700 results found

Forlano R, Martinez-Gili L, Takis P, Miguens Blanco J, Liu T, Triantafyllou E, Skinner C, Loomba R, Thursz M, Marchesi JR, Mullish BH, Manousou Pet al., 2024, Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus, Gut Microbes, Vol: 16, ISSN: 1949-0976

Aberration of the “gut-liver axis” contributes to the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we use multi-omics to analyze the gut microbiota composition and metabolic profile of patients with type-2 diabetes mellitus (T2DM). T2DM patients were screened for liver disease by blood tests, ultrasound, and liver stiffness measurements. Stool microbiota was analyzed by 16S rRNA gene sequencing; metabolomic profiling by Nuclear Magnetic Resonance spectroscopy and Ultra-High Performance-Mass Spectrometry. Microbiome and metabolic signatures were analyzed in the whole cohort and in matched subsets to identify signatures specific for steatosis (MASLD±) or fibrosis (Fibrosis±). Gut permeability was assessed in-vitro using monolayers of MDCK cells and trans-epithelial electric resistance (TEER). Cytokine profile was assessed in serum and stools.Overall, 285 patients were enrolled: 255 serum, 252 urine and 97 stool samples were analyzed. Anaeroplasma and Escherichia/Shigella ASVs were higher, while Butyricicoccus ASVs were lower in those with normal liver. In MASLD±, Butyricicoccus ASV was significantly higher in those with steatosis. In the Fibrosis±, Butyricicoccus ASV was significantly lower in those with fibrosis. Glycochenodeoxycholic acid-3-sulfate (G-UDCA-3S) appeared to be higher in MASLD with fibrosis. Fecal water from patients with MASLD and fibrosis caused the greatest drop in the TEER vs those with normal liver; this was reversed with protease inhibitors. Finally, fecal IL-13 was lower in MASLD with fibrosis. We identified microbiome signatures which were specific for steatosis and fibrosis and independent of other metabolic risk factors. Moreover, we conclude that protease-related gut permeability plays a role in those MASLD patients with fibrosis, and that disease progression is linked to a gut-liver axis which is at least partially independent of T2DM.

Journal article

Tyson LD, Atkinson S, Hunter RW, Thursz M, Vergis Net al., 2024, Editorial: Unmasking the silent threat-acute kidney injury in alcohol-associated hepatitis. Authors' reply., Aliment Pharmacol Ther, Vol: 59, Pages: 124-125

Journal article

Nguyen LBL, Lemoine M, Ndow G, Ward ZJ, Hallet TB, D'Alessandro U, Thursz M, Nayagam S, Shimakawa Yet al., 2024, Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis., Lancet Glob Health, Vol: 12, Pages: e66-e78

BACKGROUND: Global elimination of hepatitis B virus (HBV) requires expanded uptake of antiviral therapy, potentially by simplifying testing algorithms, especially in resource-limited countries. We evaluated the effectiveness, cost-effectiveness, and budget impact of three strategies that determine eligibility for anti-HBV treatment, as compared with the WHO 2015 treatment eligibility criteria, in The Gambia. METHODS: We developed a microsimulation model of natural history using data from the Prevention of Liver Fibrosis and Cancer in Africa programme (known as PROLIFICA) in The Gambia, for an HBV-infected cohort of individuals aged 20 years. The algorithms included in the model were a conventional strategy using the European Association for the Study of the Liver (EASL) 2017 criteria, a simplified algorithm using hepatitis B e antigen and alanine aminotransferase (the Treatment Eligibility in Africa for the Hepatitis B Virus [TREAT-B] score), a Treat All approach for all HBV-infected individuals, and the WHO 2015 criteria. Outcomes to measure effectiveness were disability-adjusted life years (DALYs) and years of life saved (YLS), which were used to calculate incremental cost-effectiveness ratios (ICERs) with the WHO 2015 criteria as the base-case scenario. Costs were assessed from a modified social perspective. A budget impact analysis was also done. We tested the robustness of results with a range of sensitiviy analyses including probabilistic sensitivity analysis. FINDINGS: Compared with the WHO criteria, TREAT-B resulted in 4877 DALYs averted and Treat All resulted in 9352 DALYs averted, whereas the EASL criteria led to an excess of 795 DALYs. TREAT-B was cost-saving, whereas the ICER for Treat All (US$2149 per DALY averted) was higher than the cost-effectiveness threshold for The Gambia (0·5 times the country's gross domestic product per capita: $352). These patterns did not change when YLS was the outcome. In a modelled cohort of 5000 adults (aged 20 yea

Journal article

Thursz M, Lingford-Hughes A, 2023, Advances in the understanding and management of alcohol-related liver disease., BMJ, Vol: 383

Alcohol-related liver disease (ALD) is a major cause of liver-related morbidity and mortality. Epidemiological trends indicate recent and predicted increases in the burden of disease. Disease progression is driven by continued alcohol exposure on a background of genetic predisposition together with environmental cofactors. Most individuals present with advanced disease despite a long history of excessive alcohol consumption and multiple missed opportunities to intervene. Increasing evidence supports the use of non-invasive tests to screen for and identify disease at earlier stages. There is a definite role for public health measures to reduce the overall burden of disease. At an individual level, however, the ability to influence subsequent disease course by modifying alcohol consumption or the underlying pathogenic mechanisms remains limited due to a comparative lack of effective, disease-modifying medical interventions. Abstinence from alcohol is the key determinant of outcome in established ALD and the cornerstone of clinical management. In those with decompensated ALD, liver transplant has a clear role. There is consensus that abstinence from alcohol for an arbitrary period should not be the sole determinant in a decision to transplant. An increasing understanding of the mechanisms by which alcohol causes liver disease in susceptible individuals offers the prospect of new therapeutic targets for disease-modifying drugs. Successful translation will require significant public and private investment in a disease area which has traditionally been underfunded when compared to its overall prevalence.

Journal article

Gudd CLC, Sheth R, Thursz MR, Triantafyllou E, Possamai LAet al., 2023, Immune checkpoint inhibitor-induced liver injury, Seminars in Liver Disease, Vol: 43, Pages: 402-417, ISSN: 0272-8087

In recent years cancer treatment has been revolutionized by the development and wide application of checkpoint inhibitor (CPI) drugs, which are a form of immunotherapy. CPI treatment is associated with immune-related adverse events, off-target tissue destructive inflammatory complications, which may affect a range of organs, with liver inflammation (hepatitis) being one of the more commonly noted events. This is a novel form of drug-induced liver injury and a rapidly evolving field, as our understanding of both the basic immunopathology of CPI hepatitis (CPI-H) and optimal clinical management, races to catch up with the increasing application of this form of immunotherapy in clinical practice. In this review, we summarize current evidence and understanding of CPI-H, from fundamental immunology to practical patient management.

Journal article

Tyson LD, Atkinson S, Hunter RW, Allison M, Austin A, Dear JW, Forrest E, Liu T, Lord E, Masson S, Nunes J, Richardson P, Ryder SD, Wright M, Thursz M, Vergis Net al., 2023, In severe alcohol-related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL-8 and micro-RNAs, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, ISSN: 0269-2813

Journal article

Khan RS, Lalor PF, Thursz M, Newsome PNet al., 2023, The role of neutrophils in alcohol-related hepatitis., J Hepatol, Vol: 79, Pages: 1037-1048

Alcohol-related liver disease is a major cause of liver disease-associated mortality, with inpatient care being a major contributor to its clinical and economic burden. Alcohol-related hepatitis (AH) is an acute inflammatory form of alcohol-related liver disease. Severe AH is associated with high short-term mortality, with infection being a common cause of death. The presence of AH is associated with increased numbers of circulating and hepatic neutrophils. We review the literature on the role of neutrophils in AH. In particular, we explain how neutrophils are recruited to the inflamed liver and how their antimicrobial functions (chemotaxis, phagocytosis, oxidative burst, NETosis) may be altered in AH. We highlight evidence for the existence of 'high-density' and 'low-density' neutrophil subsets. We also describe the potentially beneficial roles of neutrophils in the resolution of injury in AH through their effects on macrophage polarisation and hepatic regeneration. Finally, we discuss how manipulation of neutrophil recruitment/function may be used as a therapeutic strategy in AH. For example, correction of gut dysbiosis in AH could help to prevent excess neutrophil activation, or treatments could aim to enhance miR-223 function in AH. The development of markers that can reliably distinguish neutrophil subsets and of animal models that accurately reproduce human disease will be crucial for facilitating translational research in this important field.

Journal article

Lemoine M, 2023, Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study, The Lancet Global Health, Vol: 11, Pages: E1383-E1392, ISSN: 2214-109X

BackgroundChronic liver disease is a major cause of premature death in sub-Saharan Africa. Efficacy of antiviral therapy among patients with hepatitis B virus (HBV)-related cirrhosis is not well established in Africa. We described the clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia and assessed the impact of tenofovir disoproxil fumarate (TDF) on survival of HBV-infected patients with cirrhosis.MethodsIn this prospective cohort study, we followed up adults who were consecutively diagnosed with cirrhosis or hepatocellular carcinoma between 2012 and 2015 in The Gambia, west Africa. Patients with chronic HBV infection and cirrhosis, without hepatocellular carcinoma, were offered TDF. Primary outcome was overall survival. To determine the effect of TDF on survival, we performed a Cox proportional hazard regression model with inverse probability of treatment weighting (IPTW) based on propensity score.FindingsOf 529 patients enrolled in this study, 336 patients (252 with hepatocellular carcinoma and 84 with cirrhosis) were analysed. Patients were predominantly male (253 [75%] men and 83 [25%] women), with a median age of 42 years (IQR 33–55). 276 (84%) of 327 of patients with data were positive for HBV biomarkers, 31 (10%) of 311 were positive for hepatitis C virus antibodies, and 22 (10%) of 223 were positive for hepatitis D virus antibodies. 64% of patients with hepatocellular carcinoma had multifocal tumour, with a median size of 7·5 cm (IQR 5·4–10·8). 173 patients with hepatocellular carcinoma and 70 patients with cirrhosis were included in the survival analysis. Median survival was 1·5 months (95% CI 1·1–2·0) in patients with hepatocellular carcinoma and 17·1 months (11·2–24·0) in patients with cirrhosis (log-rank p<0·0001). In patients with hepatocellular carcinoma, ascites (hazard ratio [HR] 1·78, 95% CI

Journal article

Vaikunthanathan T, Landmann E, Correa DM, Romano M, Trevelin SC, Peng Q, Crespo E, Corrado M, Lozano J-J, Pearce EL, Perpinan E, Zoccarato A, Siew L, Edwards-Hicks J, Khan R, Luu N-T, Thursz MR, Newsome PN, Martinez-Llordella M, Shah N, Lechler RI, Shah AM, Sanchez-Fueyo A, Lombardi G, Safinia Net al., 2023, Dysregulated anti-oxidant signalling and compromised mitochondrial integrity negatively influence regulatory T cell function and viability in liver disease, EBIOMEDICINE, Vol: 95, ISSN: 2352-3964

Journal article

Arab JP, Addolorato G, Mathurin P, Thursz MRet al., 2023, Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol: 21, Pages: 2124-2134, ISSN: 1542-3565

Journal article

Nayagam S, de Villiers MJ, Shimakawa Y, Lemoine M, Thursz MR, Walsh N, Hallett TBet al., 2023, Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study, The Lancet Gastroenterology & Hepatology, Vol: 8, Pages: 635-645, ISSN: 2468-1253

BACKGROUND: In 2020, WHO recommended the addition of peripartum antiviral prophylaxis (PAP) to hepatitis B birth dose vaccination (HepB-BD) and hepatitis B infant vaccination (HepB3) to reduce mother-to-child transmission of hepatitis B virus (HBV) infection in pregnant women who have a marker of high infectivity (ie, HBV DNA ≥200 000 international units per mL or HBeAg-positive). We aimed to evaluate the impact and cost-effectiveness of this recommendation and of a theoretical simplified strategy whereby PAP is given to all pregnant women who are HBsAg-positive without risk stratification. METHODS: This modelling study used a dynamic simulation model of the HBV epidemic in 110 countries in all WHO regions, structured by age, sex, and country. We assessed three strategies of scaling up PAP for pregnant women: PAP for those with high viral load (PAP-VL); PAP for those who are HBeAg-positive (PAP-HBeAg); and PAP for all pregnant women who are HBsAg-positive (PAP-universal), in comparison with neonatal vaccination alone (HepB-BD). We investigated how different diagnostic and antiviral drug costs affected the cost-effectiveness of the strategies evaluated. Using a health-care provider perspective, we calculated incremental cost-effectiveness ratios in cost (US$) per disability-adjusted life-year (DALY) averted in each country's population and compared these with country-specific cost-effectiveness thresholds. We also calculated new neonatal infections averted for each of the strategies. FINDINGS: Adding PAP-VL to HepB-BD could avert around 1·1 million (95% uncertainty interval 1·0 million-1·2 million) new neonatal infections by 2030 and around 3·2 million (95% uncertainty interval 3·0 million-3·4 million) new neonatal infections and approximately 8·8 million (7·8 million-9·7 million) DALYs by 2100 across all the countries modelled. This strategy would probably be cost-effective up to 2100 in 28 (26

Journal article

Shimakawa YUSUKE, Ndow GIBRIL, Kaneko ATSUSH, Aoyagi KATSUM, Lemoine MAUD, Tanaka YASUHITOet al., 2023, Rapid Point-of-Care Test for Hepatitis B Core-Related Antigen to Diagnose High Viral Load in Resource-Limited Settings, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol: 21, Pages: 1943-1948, ISSN: 1542-3565

Journal article

Argemi J, Latasa MU, Atkinson SR, Blokhin IO, Massey V, Gue JP, Cabezas J, Lozano JJ, Van Booven D, Bell A, Cao S, Vernetti LA, Arab JP, Ventura-Cots M, Edmunds LR, Fondevila C, Starkel P, Dubuquoy L, Louvet A, Odena G, Gomez JL, Aragon T, Altamirano J, Caballeria J, Jurczak MJ, Taylor DL, Berasain C, Wahlestedt C, Monga SP, Morgan MY, Sancho-Bru P, Mathurin P, Furuya S, Lackner C, Rusyn I, Shah VH, Thursz MR, Mann J, Avila MA, Bataller Ret al., 2023, Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (vol 10, 3126, 2019), NATURE COMMUNICATIONS, Vol: 14

Journal article

Jambulingam N, Forlano R, Preston B, Mullish BH, Portone G, Baheer Y, Yee M, Goldin R, Thursz M, Manousou Pet al., 2023, Metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease, International Journal of Molecular Sciences, Vol: 24, Pages: 1-12, ISSN: 1422-0067

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, with fibrosis stage being the main predictor for clinical outcomes. Here, we present the metabolic profile of NAFLD patients with regards to fibrosis progression. We included all consecutive new referrals for NAFLD services between 2011 and 2019. Demographic, anthropometric and clinical features and noninvasive markers of fibrosis were recorded at baseline and at follow-up. Significant and advanced fibrosis were defined using liver stiffness measurement (LSM) as LSM ≥ 8.1 kPa and LSM ≥ 12.1 kPa, respectively. Cirrhosis was diagnosed either histologically or clinically. Fast progressors of fibrosis were defined as those with delta stiffness ≥ 1.03 kPa/year (25% upper quartile of delta stiffness distribution). Targeted and untargeted metabolic profiles were analysed on fasting serum samples using Proton nuclear magnetic resonance (1H NMR). A total of 189 patients were included in the study; 111 (58.7%) underwent liver biopsy. Overall, 11.1% patients were diagnosed with cirrhosis, while 23.8% were classified as fast progressors. A combination of metabolites and lipoproteins could identify the fast fibrosis progressors (AUROC 0.788, 95% CI: 0.703–0.874, p < 0.001) and performed better than noninvasive markers. Specific metabolic profiles predict fibrosis progression in patients with nonalcoholic fatty liver disease. Algorithms combining metabolites and lipids could be integrated in the risk-stratification of these patients.

Journal article

Schmit N, Nayagam A, Lemoine M, Ndow G, Shimakawa Y, Thursz M, Hallett Tet al., 2023, Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in The Gambia, Journal of Global Health, Vol: 13, Pages: 1-11, ISSN: 2047-2978

Background:Clinical management of chronic hepatitis B virus (HBV) infection is complex and access to antiviral treatment remains limited in sub-Saharan Africa. International guidelines recommend monitoring at least annually for disease progression among HBV-infected people not meeting treatment criteria at initial diagnosis. This study aimed to assess the impact and cost-effectiveness of alternative strategies for monitoring.Methods:We used a mathematical model of HBV transmission and natural history, calibrated to all available West African data, to project the population-level health impact, costs and cost-effectiveness of different monitoring strategies for HBV-infected individuals not initially eligible for antiviral treatment. We assumed that these patients were found in the year 2020 in a hypothetical community-based screening programme in The Gambia. Monitoring frequencies were varied between every 5 and every 1 year and targeted different age groups.Results:The currently recommended annual monitoring frequency was likely to be not cost-effective in comparison with other strategies in this setting. 5-yearly monitoring in 15-45-year olds, at US$338 per disability-adjusted life year averted, had the highest probability of being the most effective cost-effective monitoring strategy.Conclusions:Monitoring less frequently than once a year is a cost-effective strategy in a community-based HBV screening and treatment programme in The Gambia, with the optimal strategy depending on the cost-effectiveness threshold. Efficiencies may be gained by prioritising the 15-45-year age group for more intensive monitoring.

Journal article

Thursz M, Sadiq F, Tree JA, Karayiannis P, Beasley DWC, Dejnirattisai W, Mongkolsapaya J, Screaton G, Wand M, Elmore MJ, Carroll MW, Matthews I, Thomas Het al., 2023, Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2 (vol 104, 001865, 2023), JOURNAL OF GENERAL VIROLOGY, Vol: 104, ISSN: 0022-1317

Journal article

Thursz M, Sadiq F, Tree JA, Karayiannis P, Beasley DWC, Dejnirattisai W, Mongkolsapaya J, Screaton G, Wand M, Elmore MJ, Carroll MW, Matthews I, Thomas Het al., 2023, Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS- CoV-2, JOURNAL OF GENERAL VIROLOGY, Vol: 104, ISSN: 0022-1317

Journal article

Whitfield JB, Seth D, Morgan TR, 2022, All-cause and liver-related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank, ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, Vol: 46, Pages: 2245-2257, ISSN: 0145-6008

Journal article

Forlano R, Stanic T, Jayawardana S, Mullish B, Yee M, Mossialos E, Goldin R, Petta S, Tsochatzis E, Thursz M, Manousou Pet al., 2022, Clinical and cost-effectiveness analysis of community-based screening strategies for non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

<jats:title>Abstract</jats:title> <jats:p>Background &amp; Aims: We investigated the prevalence of non-alcoholic fatty liver disease(NAFLD) in patients with type 2 diabetes mellitus(T2DM) in primary care and developed a risk-stratification pathway. We also assessed the cost-utility of different screening strategies for NAFLD in the diabetic community.Methods Consecutive T2DM patients underwent screening for liver diseases, including liver stiffness measurement(LSM). Binary logistic was used to predict factors associated with significant fibrosis. We used independent predictors of significant and advanced fibrosis to generate a predictive score for this population (BIMAST),and validated it internally and externally. Five screening strategies were compared against standard of care (SOC): BIMAST score, ultrasound plus abnormal liver function tests, FIB-4, NAFLD fibrosis score, and fibroscan. A Markov model was built upon four health states based on fibrosis status. We generated the cost per quality-adjusted life year(QALY) gained and calculated the incremental cost-effectiveness ratio (ICER) in the base-case analysis conducted over a lifetime horizon.Results Among 300 patients enrolled (287 included), 64% (186) had NAFLD and 10% (28) other causes of liver disease. Patients with significant fibrosis, advanced fibrosis, and cirrhosis due to NAFLD accounted for 17% (50/287), 11% (31/287), and 3% (8/287), respectively. BIMAST score validation showed an excellent diagnostic performance in primary care improving false negatives from 38–10% compared to FIB-4. In the cost-utility analysis, ICER was £2,337.92/QALY for BIMAST and £2,480/QALY for fibroscan. When transition probabilities, utilities, screening effect, and cost inputs were modified, we found a &gt; 99% probability of NAFLD screening tests being cost-effective compared to SOC in all evaluated scenarios.Conclusion Screening for NAFLD in diabetic patient

Journal article

Sow A, Lemoine M, Toure PS, Diop M, Lo G, De Veiga J, Pape OT, Seck K, Ndow G, Bojang L, Kane A, Oudiane M, Howell J, Nayagam S, Moutchia J, Chemin I, Mendy M, Toure-Kane C, Thursz M, Ka M, Shimakawa Y, Mboup Set al., 2022, HBV continuum of care using community- and hospital-based screening interventions in Senegal: Results from the PROLIFICA programme, JHEP REPORTS, Vol: 4

Journal article

Lucey MR, Thursz MR, 2022, We need a new approach to clinical trials in alcohol-associated hepatitis: Is there a lesson in RECOVERY?, HEPATOLOGY, Vol: 76, Pages: 909-910, ISSN: 0270-9139

Journal article

Ndow G, Cessay A, Cohen D, Shimakawa Y, Gore ML, Tamba S, Ghosh S, Sanneh B, Baldeh I, Njie R, D'Alessandro U, Mendy M, Thursz M, Chemin I, Lemoine Met al., 2022, Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa., Journal of Infectious Diseases, Vol: 226, Pages: 862-870, ISSN: 0022-1899

BACKGROUND: Prevalence of occult hepatitis B infection (OBI) and its clinical outcomes have been poorly studied in Africa. METHOD: Using the PROLIFICA cohort, we compared the prevalence of OBI between HBsAg-negative healthy adults screened from the general population (controls) and HBsAg-negative patients with advanced liver disease (cases) and estimated the population attributable fraction for the effect of OBI on advanced liver disease. RESULTS: OBI prevalence was significantly higher among the cases (15/82, 18.3%) than in the control group (31/330, 9.4%, p=0.03). Among participants with OBI, pre-S2 mutations were detected in 5/31 (16.1%) controls and 3/14 (21.4%) cases (p=0.7).After adjusting for age, sex, and anti-HCV serology, OBI was significantly associated with advanced liver disease [OR: 2.8 (95% CI: 1.3-6.0), p=0.006]. In HBsAg-negative people, the proportions of advanced liver disease cases attributable to OBI and HCV were estimated at 12.9% (7.5-18.1%) and 16.9% (15.2-18.6%), respectively. CONCLUSION: OBI is endemic and an independent risk factor of advanced liver disease in The Gambia, West Africa. This implies that HBsAg-negative people with liver disease should be systematically screened for OBI. Moreover, the impact of infant hepatitis B immunization to prevent end-stage liver disease might be higher than previous estimates based solely on HBsAg-positivity.

Journal article

Ryan JM, Adams H, Tsou HL, Devshi D, Harris N, Sieh YX, Hadzhiolova T, Pavlova S, Fairclough S, Atkinson S, Tyson L, Wright G, Patel V, Evans A, Simonova M, Katzarov K, Shawcross DL, Bajaj J, Fagan A, McQuillin A, Thursz M, Morgan MY, Riva A, Chokshi Set al., 2022, Interferon lambda 4 genetic variants are associated with bacterial infection during alcohol-related liver disease, Publisher: WILEY, Pages: 85-85, ISSN: 0145-6008

Conference paper

U MRA, Shen EY-L, Cartlidge C, Alkhatib A, Thursz MR, Waked I, Gomaa AI, Holmes E, Sharma R, Taylor-Robinson SDet al., 2022, Optimised systematic review tool: Application to candidate biomarkers for the diagnosis of hepatocellular carcinoma, Cancer Epidemiology, Biomarkers and Prevention, Vol: 31, Pages: 1261-1274, ISSN: 1055-9965

This review aims to develop an appropriate review tool for systematically collating metabolites that are dysregulated in disease and applies the method to identify novel diagnostic biomarkers for hepatocellular carcinoma (HCC). Studies that analysed metabolites in blood or urine samples where HCC was compared with comparison groups (healthy, pre-cirrhotic liver disease, cirrhosis) were eligible. Tumour tissue was included to help differentiate primary and secondary biomarkers. Searches were conducted on Medline and EMBASE. A bespoke 'risk-of-bias' tool for metabolomic studies was developed adjusting for analytical quality. Discriminant metabolites for each sample type were ranked using a weighted score accounting for the direction and extent of change and the risk of bias of the reporting publication. A total of 84 eligible studies were included in the review (54 blood, 9 urine and 15 tissue), with six studying multiple sample types. High-ranking metabolites, based on their weighted score, comprised energy metabolites, bile acids, acylcarnitines and lysophosphocholines. This new review tool addresses an unmet need for incorporating quality of study design and analysis to overcome the gaps in standardisation of reporting of metabolomic data. Validation studies, standardised study designs and publications meeting minimal reporting standards are crucial for advancing the field beyond exploratory studies.

Journal article

Forlano R, Stanic T, Jayawardana S, Mullish BH, Yee M, Thursz M, Mossialos E, Manousou Pet al., 2022, Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes melllitus, JOURNAL OF HEPATOLOGY, Vol: 77, Pages: S444-S444, ISSN: 0168-8278

Journal article

Lambert J, Vergis N, Allison M, Austin A, Forrest E, Lord E, Masson S, Richardson P, Ryder S, Wright M, Thursz M, Atkinson Set al., 2022, Socio-economic factors and healthcare setting are independently associated with medium and long-term outcomes from alcohol-related hepatitis, Publisher: ELSEVIER, Pages: S124-S125, ISSN: 0168-8278

Conference paper

Shimakawa Y, Ndow G, Cerceau T, Ceesay A, Hasegawa A, Kaneko A, Aoyagi K, Vincent JP, Watanabe T, Baba M, Sanneh B, Baldeh I, Njie R, D'Alessandro U, Mendy M, Chemin I, Thursz M, Lemoine M, Tanaka Yet al., 2022, Rapid point-of-care test for hepatitis B core-related antigen (HBcrAg) to identify HBV-infected patients eligible for antiviral therapy., Publisher: ELSEVIER, Pages: S295-S295, ISSN: 0168-8278

Conference paper

Tyson LD, Atkinson S, Allison M, Austin A, Cross L, Dear J, Forrest E, Liu T, Lord E, Masson S, Nunes J, Richardson P, Ryder S, Wright M, Thursz M, Vergis Net al., 2022, Incident acute kidney injury in severe alcohol-related hepatitis is strongly associated with mortality and can be predicted using micro-RNAs and markers of systemic inflammation, Publisher: ELSEVIER, Pages: S122-S122, ISSN: 0168-8278

Conference paper

Ndow G, Ceesay A, Shimakawa Y, Jallow AO, Nyang H, Bittaye B, Mendy F, Secka O, D'Alessandro U, Thursz M, Chemin I, Lemoine Met al., 2022, Concordance of the Xpert hepatitis B viral load test and conventional quantitative PCR in detecting and quantifying viremia using stored plasma and dried blood spot samples in West Africa, Publisher: ELSEVIER, Pages: S258-S259, ISSN: 0168-8278

Conference paper

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00104777&limit=30&person=true